ONCOSYS-OVA prospective study is identifying effective therapeutic strategies for high-grade serous ovarian cancer (HGSC).
This project will establish a state-of-the-art infrastructure to systematically collect, analyze and interpret functional, molecular and clinical data in ovarian cancer. This enables enhanced designing of clinical studies, implementation of new diagnostic methods and will increase communication between clinical, translational and basic science specialists.
To this end, Oncosys-OVA collaborates with several top laboratories. All research data is treated in an anonymous manner according to the ethical principles of the Helsinki University Hospital and the EU.
The ONCOSYS-OVA collaborators are:
The Pirinen Lab, University of Helsinki
Eija Pirinen’s Mitochondria and nutrient signaling lab investigates mitochondrial metabolism in high grade serous ovarian cancer. The main focus of the research is to understand how mitochondrial metabolism affects patient’s chemotherapy response and whether metabolic modulators could be used in combination with current first-line chemotherapy to enhance chemotherapy response in chemoresistant patients.